📰 Newspapers

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Daily pill daraxonrasib appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest cancers.

Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades - a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers.

Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in early medical trials.

Tumours stopped growing in almost all of the 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

But doctors stress it is a long way from knowing how long it might keep the disease at bay and should not be seen as a cure.

Cancer Research UK called it "the biggest leap forward in decades" for pancreatic cancer patients.

The charity's Dr Sam Godfrey told BBC News that the results were incredibly exciting. "What this new drug has done is it's found a way of drugging the undruggable.

"We are finally seeing progress in pancreatic cancer which is so long overdue."

Pancreatic cancer is notoriously hard to treat and has the lowest survival rate of all common cancers in the UK.

Although chemotherapy can shrink tumours a bit, the cancer often grows again.

Most patients with advanced disease survive months, not years.

In brief

Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades - a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers. Cancer Research UK called it "the biggest leap forward in decades" for pancreatic cancer patients. Although chemotherapy can shrink tumours a bit, the cancer often grows again.

This is the opening of the story, shared with credit to BBC News — Top Stories. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at BBC News — Top Stories ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.